439 related articles for article (PubMed ID: 25311296)
1. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
3. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
4. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
6. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
7. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted endocrine therapies for breast cancer.
Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
[TBL] [Abstract][Full Text] [Related]
10. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
12. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Harwood KV
Clin J Oncol Nurs; 2004 Dec; 8(6):629-37. PubMed ID: 15637958
[TBL] [Abstract][Full Text] [Related]
13. Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action.
Glück S
Clin Breast Cancer; 2014 Apr; 14(2):75-84. PubMed ID: 24355138
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S
Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
17. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
19. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
